Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of N-Deschlorobenzoyl indomethacin Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of N-Deschlorobenzoyl indomethacin

CAS No. :	2882-15-7
Formula :	C₁₂H₁₃NO₃
M.W :	219.24
SMILES Code :	O=C(O)CC1=C(C)NC2=C1C=C(OC)C=C2
MDL No. :	MFCD00005618
InChI Key :	TXWGINUZLBAKDF-UHFFFAOYSA-N
Pubchem ID :	76151

Safety of N-Deschlorobenzoyl indomethacin

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of N-Deschlorobenzoyl indomethacin

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 2882-15-7 ]

[ 2882-15-7 ] Synthesis Path-Downstream 1~35

1
[ 1002-69-3 ]
[ 2882-15-7 ]
[ 909390-44-9 ]

References: [1]Journal of Chemical Research,2005,p. 640 - 642.

2
[ 67-56-1 ]
[ 2882-15-7 ]
[ 7588-36-5 ]

Yield	Reaction Conditions	Operation in experiment
100%		General procedure: A reaction mixture containing the indoleacetic acid derivative (1 equivalent) and BOP-Cl (1 equivalent) in 3 mL/mmol of anhydrous CH2Cl2 is treated with triethylamine (2 equivalents) and aged at ambient temperature for 5 min. The mixture is combined with anhydrous methanol (0.14 mL/mmol) and then continuously stirred overnight at room temperature. Following dilution with dichloromethane (12 mL/mmol), the organic solution is washed with water (2x6 mL/mmol), dried over Na2SO4, and filtered. The organic filtrate is collected and concentrated in vacuo and the crude ester is purified by flash chromatography on silica gel (ethyl acetate/hexane gradient) to afford the title compound at first as viscous yellow oil, which stably crystallizes upon seeding and subsequent cold storage.
83%	With chloro-trimethyl-silane; at 20℃;	General procedure: Indomethacin (3.00 g, 8.39 mmol) was dissolved in 1 M NaOH(200 mL) and left to stir overnight. The reaction was acidified with1 M HCl and the precipitate filtered off. Filtrate was then extractedthree times with DCM (100 mL). Combined organic layer was driedover Na2SO4 and concentrated in vacuo to give crude 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetic acid (1.12 g, 5.15 mmol). Thecrude intermediate was dissolved in MeOH (50 mL) and TMSCl(1.86 mL, 14.73 mmol) was added. The reaction mixture was leftto stir at room temperature overnight. Water (50 mL) was addedto quench the reaction and extracted three times with DCM(50 mL). Organic layer was combined, dried over Na2SO4 and concentratedin vacuo. Residue obtained was purified by column chromatographyusing CHCl3:EtOAc (10:1) to give 12 as a brown solid(0.99 g, 83%). 1H NMR (400 MHz, CDCl3) d 7.92 (s, 1H), 7.07 (d,J = 8.7 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.81-6.75 (m, 1H), 3.87 (d,J = 1.1 Hz, 3H), 3.68 (d, J = 1.0 Hz, 5H), 2.32 (s, 3H). 13C NMR(101 MHz, CDCl3) d 172.8, 154.1, 133.7, 130.2, 129.0, 111.1,110.8, 104.1, 100.4, 55.9, 51.9, 30.3, 11.7.

References: [1]Tetrahedron,2012,vol. 68,p. 10049 - 10058,10.
[2]Bioorganic and Medicinal Chemistry,2017,vol. 25,p. 1202 - 1218.
[3]Bioorganic and Medicinal Chemistry,2012,vol. 20,p. 4830 - 4837.
[4]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

3
[ 560998-03-0 ]
[ 2882-15-7 ]
CH₃OC₄H₂C₃N₄SCH₂C₈H₄NO(CH₃)2 [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2007,vol. 42,p. 823 - 840.

4
[ 945221-26-1 ]
[ 2882-15-7 ]
ClCH₃OC₆H₃C₃N₄SCH₂C₈H₄NO(CH₃)2 [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2007,vol. 42,p. 823 - 840.

5
[ 568570-11-6 ]
[ 2882-15-7 ]
(CH₃O)2C₆H₃C₃N₄SCH₂C₈H₄NO(CH₃)2 [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2007,vol. 42,p. 823 - 840.

6
[ 2882-15-7 ]
[ 68641-49-6 ]
CH₃OC₈H₄N(CH₃)CH₂COOOP(C₃H₄NO₂)2 [ No CAS ]

References: [1]Journal of the American Chemical Society,2006,vol. 128,p. 14264 - 14265.

7
[ 2882-15-7 ]
2-(3"-(5"-methoxy-2"-methylindolyl)ethyloxy)adenosine [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

8
[ 2882-15-7 ]
[ 936252-38-9 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

9
[ 2882-15-7 ]
[ 1026166-41-5 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

10
[ 2882-15-7 ]
[ 936253-34-8 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

11
[ 2882-15-7 ]
[ 936252-78-7 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.

12
[ 2882-15-7 ]
[ 26766-01-8 ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1810 - 1827.
[2]Archiv der Pharmazie,1988,vol. 321,p. 377 - 383.

13
[ 2882-15-7 ]
[ 871483-23-7 ]